ChiCTR2200055107 版本V1.4 版本创建时间2023/01/08 22:41:03 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200055107 

最近更新日期:

Date of Last Refreshed on:

2022-07-16 14:50:54 

注册时间:

Date of Registration:

2022-01-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

重复经颅磁刺激对轻、中度阿尔茨海默病患者认知和脑功能的影响

Public title:

Effects of repetitive transcranial magnetic stimulation on cognition and brain function in patients with mild to moderate Alzheimer's disease

注册题目简写:

rTMS对AD患者认知和脑功能的影响

English Acronym:

Effects of rTMS on cognition and brain function in AD patients

研究课题的正式科学名称:

重复经颅磁刺激对轻、中度阿尔茨海默病患者认知和脑功能的影响

Scientific title:

Effects of repetitive transcranial magnetic stimulation on cognition and brain function in patients with mild to moderate Alzheimer's disease

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

胡月青 

研究负责人:

胡月青 

Applicant:

Hu Yueqing 

Study leader:

Hu Yueqing 

申请注册联系人电话:

Applicant telephone:

+86 10 83183801

研究负责人电话:

Study leader's telephone:

+86 10 83183801

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

hyqing1987@163.com

研究负责人电子邮件:

Study leader's E-mail:

hyqing1987@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市海淀区温泉路118号北京老年医院精神心理二科

研究负责人通讯地址:

北京市海淀区温泉路118号北京老年医院精神心理二科

Applicant address:

118 Wenquan Road, Haidian District, Beijing

Study leader's address:

118 Wenquan Road, Haidian District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

100095

研究负责人邮政编码:

Study leader's postcode:

100095

申请人所在单位:

北京老年医院

Applicant's institution:

Beijing Geriatric Hospital

研究负责人所在单位:

北京老年医院

Affiliation of the Leader:

Beijing Geriatric Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

BJLNYY-伦审-批第2021-012号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

北京老年医院伦理委员会

Name of the ethic committee:

Ethics Committee of Beijing Geriatric Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2021-12-20 00:00:00

伦理委员会联系人:

李春璐

Contact Name of the ethic committee:

Li Chunlu

伦理委员会联系地址:

北京市海淀区温泉路118号北京老年医院科技处

Contact Address of the ethic committee:

118 Wenquan Road, Haidian District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京老年医院

Primary sponsor:

Beijing Geriatric Hospital

研究实施负责(组长)单位地址:

北京市海淀区温泉路118号

Primary sponsor's address:

118 Wenquan Road, Haidian District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京老年医院

具体地址:

海淀区温泉路118号

Institution
hospital:

Beijing Geriatric Hospital

Address:

118 Wenquan Road, Haidian District

经费或物资来源:

北京老年医院老年医学科研专项项目资助

Source(s) of funding:

Funded by the Special Project of Geriatrics Research in Beijing Geriatrics Hospital

Target disease:

Alzheimer's disease (AD)

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

通过随机对照试验评价重复性经颅磁刺激(rTMS)刺激双侧角回对轻、中度AD患者的认知功能的临床疗效和安全性,同时通过fMRI分析脑功能变化。  

Objectives of Study:

A randomized controlled trial was conducted to evaluate the clinical efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) stimulation of bilateral angular gyrus on cognitive function in patients with mild to moderate AD, and brain function changes were analyzed by fMRI.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.临床确诊的或很可能的AD患者,MMSE评分在10-26分之间,且有头颅影像学的诊断依据。病程10年以内。
2.年龄≥60周岁,性别不限,能配合rTMS和脑功能磁共振检查者,无检查禁忌症。
3.如正在服用AD药物,则需药物服用已≥4周,且在治疗期间无药物剂量调整。
4.受试者的监护人同意参加本项研究,并签署知情同意书。

Inclusion criteria

1. Clinically diagnosed or probable AD patients, MMSE score between 10-26 points, and a diagnosis based on head imaging. Disease duration within 10 years.
2. Aged >= 60 years, gender is not limited, and those who can cooperate with rTMS and brain functional magnetic resonance examination have no contraindications.
3. If you are taking AD drugs, you need to take the drug for >=4 weeks, and there is no drug dose adjustment during the treatment period.
4. The patients' guardians agree to participate in this study and sign the informed consent.

排除标准:

1.有经颅磁刺激治疗禁忌症:如安装有心脏起搏器、冠脉支架和动脉瘤夹等金属内置物者,安装有人工植入耳蜗等铁磁材料者;
2.合并重要脏器(心、肺、肝、肾等)的功能衰竭和病情危重者;
3.长期嗜酒、滥用药物者;
4.严重视听障碍者;
5.有器质性精神病、传染病、脑外伤及手术史者;
6.有癫痫病史者;
7.正在进行其它临床试验者。

Exclusion criteria:

1. There are contraindications for transcranial magnetic stimulation: such as those with metal implants such as pacemakers, coronary stents and aneurysm clips, and those with ferromagnetic materials such as cochlear implants;
2. Combined with functional failure and critical illness of important organs (heart, lung, liver, kidney, etc.);
3. Long-term alcoholism and drug abuse;
4. Severe hearing-impaired persons;
5. Those with a history of organic mental illness, infectious diseases, traumatic brain injury and surgery;
6. Those with a history of epilepsy;
7. Those who are undergoing other clinical trials.

研究实施时间:

Study execute time:

From 2022-01-01 00:00:00 To 2024-12-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-01-01 00:00:00 To 2024-01-01 00:00:00  

干预措施:

Interventions:

组别:

试验组

样本量:

20

Group:

Experimental group

Sample size:

干预措施:

rTMS真刺激

干预措施代码:

Intervention:

rTMS stimulation

Intervention code:

组别:

对照组

样本量:

20

Group:

Control group

Sample size:

干预措施:

rTMS伪刺激

干预措施代码:

Intervention:

rTMS pseudostimulation

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

北京老年医院 

单位级别:

三级 

Institution
hospital:

Beijing Geriatric Hospital

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

ADAS-cog评分

指标类型:

主要指标

Outcome:

Alzheimer's Disease Rating Scale - Cognitive Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

MMSE评分

指标类型:

次要指标

Outcome:

Mini-Mental State Examination Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

MoCA评分

指标类型:

次要指标

Outcome:

Montreal Cognitive Assessment Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

NPI评分

指标类型:

次要指标

Outcome:

Neuropsychiatric Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

BI评分

指标类型:

次要指标

Outcome:

Barthel Index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

静息态功能核磁共振图像

指标类型:

次要指标

Outcome:

Resting-state fMRI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良反应

指标类型:

次要指标

Outcome:

Adverse reactions

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

Null

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 60 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究采用完全随机分组方法,将入组患者按照就诊顺序编号,利用SPSS 25.0生成随机数字表,产生观察单位编号和随机数字,一一对应,将全部随机数字从小到大编序号,按预先规定的序号前1/2为试验组,后1/2为对照组.

Randomization Procedure (please state who generates the random number sequence and by what method):

This research adopts the completely randomized method, which will recruit the patients in medical order number (considerated as observation number), using SPSS 25.0 to generate random numbers table, then match the observation number and random numbers, one to one correspondence, will all random numbers from small t

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究后发表文章

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The paper will be published after the study

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2022-01-01 00:10:34